The Cardiotoxicity Market Report by DelveInsight provides a detailed understanding of Cardiotoxicity, historical and forecasted epidemiology, and Cardiotoxicity market trends in the 7MM (United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan).
Some Key Highlights from the Cardiotoxicity Market Report
Cardiotoxicity was found in 39.6% of anthracycline-treated patients in a recent study (Sendon et al., 2020).
Cardiotoxicity also seen in patients who were taking anti-HER2 (43.5%), anthracycline and anti-HER2 (45.7%), TKI (50%), left breast radiotherapy (44.8%), and mediastinal radiotherapy (29.1%). (Sendon et al., 2020).
Around one-third of cancer patients who receive chemotherapy drugs including trastuzumab (Herceptin) and anthracyclines have heart cell damage (University of Michigan, n.d.).
Cardiotoxicity pipeline therapies include Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), and others.
Moleculin Biotech, Monopar Therapeutics, among others are the major pharmaceutical companies in the Cardiotoxicity market.
To gain more insights request sample @ Cardiotoxicity Market Insights Report
Cardiotoxicity report includes the current clinical practises, new drugs, Cardiotoxicity market share of individual therapies, current and forecasted Cardiotoxicity market size from 2018 to 2030 segmented by seven major markets.
Cardiotoxicity: Disease Overview
Cardiotoxicity occurs when the heart muscle is damaged. Chemotherapy drugs or treatments for other diseases may cause Cardiotoxicity. As a result Cardiotoxicity causes the heart to weaken and become unable to pump blood across the body.
Several cancer drugs and therapies will damage the heart directly. Heart failure, high blood pressure, low blood pressure, heart attacks, rapid heartbeat, slow heart rate, or fluid around the heart are all possible side effects of these medications.
Cardiotoxicity Epidemiology Segmentation
Various Cancer Total Incident Cases
Various Cancer Total Number of Patients taking Chemotherapy
Cardiotoxicity Total Number of Patients taking Specific Chemotherapy Agents
Cardiotoxicity Total Number of Patients
Cardiotoxicity Treatment Landscape
The doctor may recommend reducing the dosage of the medication that caused the heart damage, stopping the medication, or switching to a different regimen, depending on the severity of the Cardiotoxicity and the patient’s overall health status. Cardiotoxicity can be treated with a variety of drugs, including:
Dexrazoxan
ACE inhibitors
Beta-blockers
Diuretics
Digoxin
Vasodilators
Cardiotoxicity Market
As people have become more conscious of this unusual symptom, medications have been developed that take into account the cardiotoxic effects. These factors will fuel the demand in the forecast period (2021–2030), along with the planned launch of emerging therapies such as Annamycin (Moleculin Biotech), Camsirubicin (Monopar Therapeutics), others in the Cardiotoxicity market.
Get more information @ Cardiotoxicity Market and Treatment Landscape
Cardiotoxicity Pipeline Therapies and Key Companies
Annamycin: Moleculin Biotech
Camsirubicin: Monopar Therapeutics
Table of Contents
1.
Report Introduction
2.
Executive Summary of Cardiotoxicity
3.
Cardiotoxicity Market Overview at a Glance
4.
Disease Background and Overview: Cardiotoxicity
5.
Case Reports of Cardiotoxicity
6.
Cardiotoxicity Patient Journey
7.
Cardiotoxicity Epidemiology and Patient Population
8.
Epidemiology of Cardiotoxicity by Countries (2018–2030)
9.
Cardiotoxicity Treatments and Medical Practices
10.
Cardiotoxicity Marketed Therapies
11.
Cardiotoxicity Emerging Therapies
12.
Cardiotoxicity Market Size
13.
7MM: Country-wise Market Analysis
14.
Cardiotoxicity Market Drivers
15.
Cardiotoxicity Market Barriers
16.
SWOT Analysis
17.
KOL Views
18.
Reimbursement and market access
19.
Report Methodology
20.
DelveInsight Capabilities
21.
Disclaimer
22.
About DelveInsight
For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts
Related Reports
Dilated Cardiomyopathy Market
Get comprehensive historical and forecast analysis of Dilated Cardiomyopathy Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Amgen, Pfizer, Vericel, Berlin Cures GmbH, MyoKardia, Cumberland Pharmaceuticals, Capricor Therapeutics, among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/